Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine 5'-diphosphate-ribose polymerase (PARP) i...
Saved in:
Main Authors: | Takehiro Nakao (Author), Kenichi Harano (Author), Masashi Wakabayashi (Author), Yoichi Naito (Author), Hiroshi Tanabe (Author), Toru Mukohara (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
by: Yin-Ting Chuang, et al.
Published: (2012) -
The Role of ADCY1 in Regulating the Sensitivity of Platinum-Based Chemotherapy in NSCLC
by: Ting Zou, et al.
Published: (2024) -
Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
by: Yin Shi, et al.
Published: (2023) -
Nanocarriers containing platinum compounds for combination chemotherapy
by: Guihua Fang, et al.
Published: (2022) -
Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
by: Afifah NN, et al.
Published: (2020)